Donepezil

Profiles of Drug Substances, Excipients and Related Methodology

Volumn 35, Issue , 2010, Pages 117-150

  Asiri, Yousif A ^a   Mostafa, Gamal A E ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84905676142     PISSN: 18715125     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1871-5125(10)35003-5     Document Type: Chapter

References (52)

1. The Merck Index, an Encyclopedia of Chemicals, Drugs, and Biologicals 2006, Merck & Co., Inc., Whitehouse Station, NJ, USA, p. 3419. 14th ed.
2. Maffat A.C., Osselton M.D., Widdop B. Clarck's Analysis of Drug and Poisons, vol. 2 2004, The Pharmaceutical Press, Royal Pharmaceutical of Great Britain, London, p. 954. third ed.
3. Sugimoto H. Structure activity relationships of acetylcholinesterase inhibitors: donepezil hydrochloride for the treatment of Alzheimer's Disease. Pure Appl. Chem. 1999, 71:2031-2037.
4. Rogers S.L., Yamanishi Y., Yamatsu K. E2020-the pharmacology of a piperidine cholinesterase inhibitor. Cholinergic Basis for Alzheimer Therapy 1991, 314-320. Birkhäuser, Boston. R. Becker, E. Giacobini (Eds.).
5. Sugimoto H., Iimura Y., Yamanishi Y., Yamatsu K. Synthesis and antiacetylcholinesterase activity of 1-benzyl-4-[(5,6-dimethoxy-1-indanon-2-yl)methyl]piperidine hydrochloride (E2020) and related compounds. Bioorg. Med. Chem. Lett. 1992, 2:871-876.
6. 14C). J. Label. Comp. Radiopharm. 1989, XXVI:835-839.
7. Sherman K. Pharmacodynamics of oral E2020 and tacrine in humans: novel approaches. Cholinergic Basis for Alzheimer Therapy 1991, 321-328. Birkhäuser, Boston. R. Becker, E. Giacobini (Eds.).
8. Rogers S.L., Friedhoff L.T. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicenter, randomized, double-blind, placebo-controlled trial. Dementia 1996, 7:293-303.
9. Rogers S.L., Friedhoff L.T., The Donepezil Study Group The efficacy and safety of Donepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind, placebo trial. Dementia 1996, 7:293-303.
10. Rogers S.L., Farlow M.R., Doody R.S., Mohs R., Friedhoff L.T., The Donepezil Study Group A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998, 50:136-145.
11. Rogers S.L., Doody R.S., Mohs R., Friedhoff L.T., The Donepezil Study Group Donepezil improves cognition and global function in Alzheimer's disease: a 15-week, double-blind, placebo-controlled study. Arch. Intern. Med. 1998, 158:1021-1031.
12. O.L. Lerman, J. Kaspi, O. Arad, M. Alnabari, Y. Sery. Process for the preparation of donepzil. U.S. Patent No., US 2004/0048893 A1.
13. L. Zelikovitch, O. Arad, M. Alnabari, Y. Sery, O. Kurlat, M. Bentolila et al., Process for alkylating secondary amines and the use in donepezil preparation thereof, U.S. Patent No., US 2006/0122227 A1.
14. J.S. Vidyadhar, N.A. Venkatraman, S.R. Pandurang, Process for the preparation of 1-benzyl-4(5,6-dimethoxy-1-indanon)-2-yl) methyl piperidine hydrochloride( donepzil HCl), U.S. Patent No., US, 2003, 6,649,765 B1.
15. T.V. Radhakrishnan, S.D. Govind, N.A. Venkatraman, Process for the preparation of 1-benzyl-4(5,6-dimethoxy-1-indanon)-2-yl) methyl piperidine hydrochloride (donepzil HCl), U.S. Patent No., US 2004, 0158070 A1.
16. N. Mahesh, G.A. Kumar, D. Ramesh, M. Sivakumaran, Process for the preparation of donepezil hydrochloride, United State Patent Application, US 2007/0191610 A1.
17. Sugimoto H., Yutaka T., Kunizou H., Norio K., Youichi L., Atsushi S., et al. J. Med. Chem. 1995, 38:481. U.S. Patent No. 5,100,901.
18. A.L. Gutman, B. Tishin, A. Vilensky, P. Potyabin, G.A. Nisnevich, Process for production of highly pure donepezil hydrochloride, U.S. Patent No., US 2004 /0192919 A1.
19. M.S. Reddy, S. Eswaraiah, M.V. Thippannachar, E.R. Chandrashekar, P.A. Kumar, United States Patent Application Publication, Novel crystalline form-VI of donepezil hydrochloride and process for the preparation thereof, United State of Patents, US2004/0229914A1.
20. U.P. Aher, V.R. Tarur, D.G. Sathe, A.V. Naidu, K.D. Sawant, Donepezil hydrochloride form VI, U.S. Patent No., US 2007/0123565 A1.
21. U.P. Aher, V.R. Tarur, D.G. Sathe, A.V. Naidu, K.D. Sawant, Polymorph of (1-benzyl-4-[(5,6-dimeththoxy-1-indanone)-2-yl] methyl piperidine hydrochloride(donepezil hydrochloride) and a process for producing thereof, U.S. Patent No., US 2005/0272775 A1.
22. I. Adin, C. Iustain, O. Arad, J. Kaspe, United States Patent Application, Crystalline forms of donepezil base, U.S. Patent No., US 2006/0122226 A1.
23. Abbas S.S., Fayez Y.M., Abdel Fattah L.-S. Stability indicating methods for determination of donepezil hydrochloride according to ICH guidelines. Chem. Pharm. Bull. 2006, 54:1447-1450.
24. Mostafa G.A.E., Hefnawy M.M., Al-Majed A. Membrane sensors for the selective determination of donepzil hydrochloride. J. AOAC Int. 2009, in press.
25. Golcu A., Ozkan S.A. Electroanalytical determination of donepezil HCl in tablets and human serum by differential pulse and Osteryoung square wave voltammetry at a glassy carbon electrode. Pharmazie 2006, 61:760-765.
26. Stella K., Stella M., Pandora A., Morfis A., Antonios B., Maria K. New gradient high-performance liquid chromatography method for determination of donepezil hydrochloride assay and impurities content in oral pharmaceutical formulation. J. Chromatogr. A 2008, 1189:392-397.
27. Norio Y.-F., Rie F., Takenori T., Tomonori T. Determination of donepezil, an acetylcholinesterase inhibitor, in human plasma by high-performance liquid chromatography with ultraviolet absorbance detection. J. Chromatogr. B 2002, 768:261-265.
28. Nakashima K., Itoh K., Kono M., Nakahima M.N., Wada M. Determination of donepezil hydrochloride in human and rat plasma, blood and brain microdialysates by HPLC with a short C30 column. J. Pharm. Biomed. Anal. 2006, 41:201-206.
29. Lu Y.H., Wen H.M., Li W., Chi Y.M., Zhang Z.X. Determination of donepezil in human plasma by HPLC-MS. Yao Xue Xue Bao 2003, 38:203-206.
30. Bhavin N.P., Naveen S., Mallika S., Pranav S.S. Quantitation of donepezil and its active metabolite 6-O-desmethyl donepezil in human plasma by a selective and sensitive liquid chromatography-tandem mass spectrometric method. Anal. Chim. Acta 2008, 629:145-157.
31. Constantinos A., Yannis D., Constantinos K., Yannis L.L. Quantitative determination of donepezil in human plasma by liquid chromatography/tandem mass spectrometry employing an automated liquid-liquid extraction based on 96-well format plates: application to a bioequivalence study. J. Chromatogr. B 2007, 848:239-244.
32. Park E.J., Lee H.W., Ji H.Y., Kim H.Y., Lee M.H., Park E.S., et al. Hydrophilic interaction chromatography-tandem mass spectrometry of donepezil in human plasma: application to a pharmacokinetic study of donepezil in volunteers. Arch. Pharm. Res. 2008, 31:1205-1211.
33. Xie Z., Liao Q., Xu X., Yao M., Wan J., Liu D. Rapid and sensitive determination of donepezil in human plasma by liquid chromatography/tandem mass spectrometry: application to a pharmacokinetic study. Rapid Commun. Mass Spectrom. 2006, 20:3193-3198.
34. Lu Y., Wen H., Li W., Chi Y., Zhang Z. Determination of donepezil hydrochloride (E2020) in plasma by liquid chromatography-mass spectrometry and its application to pharmacokinetic studies in healthy, young, Chinese subjects. J. Chromatogr. Sci. 2004, 42:234-237.
35. Mahasen A.R., Heba H.A., Bushra T.A., Hassan Y.A.-E., Kenichiro N. Stereoselective HPLC assay of donepezil enantiomers with UV detection and its application to pharmacokinetics in rats. J. Chromatogr. B. 2006, 830:114-119.
36. Haginaka J., Seyama C. Determination of enantiomers of 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine hydrochloride (E2020), a centrally acting acetylcholine esterase inhibitor, in plasma by liquid chromatography with fluorometric detection. J. Chromatogr. 1992, 577:95-102.
37. Kenji M., Yoshiya O., Hiroshi N., Tsutomu Y. Simultaneous determination of donepezil (Aricept®) enantiomers in human plasma by liquid chromatography-electrospray tandem mass spectrometry. J. Chromatogr. B. 1999, 729:147-155.
38. Odd Y., Ohe H., Tanaka S., Asakawa N. Direct determination of E2020 enantiomers in plasma by liquid chromatography-mass spectrometry and column-switching techniques. J. Chromatogr. A. 1995, 694:209-218.
39. Lu Y.H., Zhang M., Meng Q., Zhang Z.X. Separation and determination of donepezil hydrochloride enantiomers in plasma by capillary electrophoresis. Yao Xue Hue Bao 2006, 41:471-475.
40. Yeh H.H., Yang Y.H., Ko J.Y., Chen S.H. Sensitive analysis of donepezil in plasma by capillary electrophoresis combining on-column field-amplified sample stacking and its application in Alzheimer's disease. Electrophoresis 2008, 29:3649-3657.
41. Tiseo P.J., Foley K., Friedhoff L.T. The effect of multiple doses of donepezil HCl on the pharmacokeinetic and pharmacodynamic profile of warfarin. Br. J. Clin. Pharmacol. 1998, 46:45-50.
42. Tiseo P.J., Foley K., Friedhoff L.T. Pharmacodynamic and pharmacokinetic of donepezil HCl profile following evening administration. Br. J. Clin. Pharmacol. 1998, 46:13-18.
43. Reyes J.F., Vargas R., Kumar D., Cullen E.I., Perdomo C.A., Pratt R.D. Steady-state pharmacokinetics, pharmacodynamics and tolerability of donepezil hydrochloride in hepatically impaired patients. Br. J. Clin. Pharmacol. 2004, 58:9-17.
44. Rogers S.L., Coope N.M., Snkoventy R., Pederson J.E., Lee J.N., Friedhoff L.T. Pharmacodynamic and pharmacokinetic of donepezil HCl profile following multiple oral doses. Br. J. Clinc. Pharmacol. 1998, 46:7-13.
45. Nagy C.F., Kumar D., Cullen E.I., Bolton W.K., Marbury T.C., Gutierrez M.J., Hutman H.W., Pratt R.D. Steady-state pharmacokinetics and safety of donepezil HCl in subjects with moderately impaired renal function. Br. J. Clin. Pharmacol. 2004, 58:18-24.
46. Tiseo P.J., Perdomo C.A., Friedhoff L.T. Concurrent administration of donepezil HCl and cimetidine: assessment of pharmacokinetic changes following single and multiple doses. Br. J. Clinc. Pharmacol. 1998, 46:25-29.
47. Mihara M., Ohnishi A., Tomono Y. Pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy male volunteers. Int. J. Clin. Pharmacol. Ther. Toxicol. 1993, 31:223-229.
48. Ohnishi A., Mihara M., Kamakura H. Comparison of the pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy young and elderly subjects. J. Clin. Pharmacol. 1993, 33:1086-1091.
49. Rogers S.L., Friedhoff L.T. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study. Eur. Neuropsychopharmacol. 1998, 8:67-75.
50. Wagstaff A.J., McTavish D.T. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in Alzheimer's disease. Drugs Aging 1994, 4:510-540.
51. Crimson M.L. First drug approved for Alzheimer's disease. Ann. Pharmacother. 1994, 28:744-751.
52. Tiseo P.J., Perdomo C.A., Friedhoff L.T. Metabolism and elimination of 14C-donepezil in healthy volunteers: a single-dose study. Br. J. Clin. Pharmacol. 1998, 46:19-24.